株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

脈絡膜新生血管:パイプライン製品の分析

Choroidal Neovascularization - Pipeline Review, H1 2017

発行 Global Markets Direct 商品コード 213111
出版日 ページ情報 英文 50 Pages
即納可能
価格
本日の銀行送金レート: 1USD=112.37円で換算しております。
Back to Top
脈絡膜新生血管:パイプライン製品の分析 Choroidal Neovascularization - Pipeline Review, H1 2017
出版日: 2017年04月28日 ページ情報: 英文 50 Pages
概要

脈絡膜新生血管膜(NCVM)とは、網膜の下部(脈絡膜)に新たに発生する血管で、視力低下を引き起こします。主な症状には、痛みを伴わない視野喪失や、変視野、色覚異常などが挙げられます。主な治療法として、抗VEGF(血管内皮増殖因子)抗体やレーザー光凝固術、光力学的療法などがあります。

当レポートでは、世界各国での脈絡膜新生血管治療用のパイプライン製品の開発状況について分析し、製品開発・上市の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要、最新の業界動向などの情報をお届けします。

イントロダクション

  • 調査範囲

脈絡膜新生血管の概要

治療薬の開発

  • パイプライン製品の概要
  • パイプライン製品の比較分析

脈絡膜新生血管:企業で開発中の治療薬

脈絡膜新生血管:大学/機関で研究中の治療薬

脈絡膜新生血管:パイプライン製品の概況

  • 後期段階の製品
  • 臨床段階の製品
  • 初期段階の製品

脈絡膜新生血管:企業で開発中の製品

脈絡膜新生血管:大学/機関で研究中の製品

脈絡膜新生血管の治療薬開発に従事している企業

  • Affitech A/S
  • F. Hoffmann-La Roche Ltd.
  • Genentech, Inc.
  • Iconic Therapeutics, Inc.
  • Mabion SA
  • Navigen Pharmaceuticals, Inc.
  • Noxxon Pharma AG
  • Promedior, Inc.
  • 三和化学研究所

脈絡膜新生血管:治療薬の評価

  • 単剤製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

脈絡膜新生血管:最近のパイプライン動向

脈絡膜新生血管:休止中のプロジェクト

脈絡膜新生血管:開発が中止された製品

脈絡膜新生血管:製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC9210IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Choroidal Neovascularization - Pipeline Review, H1 2017, provides an overview of the Choroidal Neovascularization (Ophthalmology) pipeline landscape.

Choroidal neovascularization (CNV) involves the growth of new blood vessels that originate from the choroid Symptoms include painless loss of vision, metamorphopsia, and color disturbances. Treatment includes ant-VEGF agents, laser photocoagulation and photodynamic therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Choroidal Neovascularization - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Choroidal Neovascularization (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Choroidal Neovascularization (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Choroidal Neovascularization and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 10 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 4 molecules, respectively.

Choroidal Neovascularization (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Choroidal Neovascularization (Ophthalmology).
  • The pipeline guide reviews pipeline therapeutics for Choroidal Neovascularization (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Choroidal Neovascularization (Ophthalmology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Choroidal Neovascularization (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Choroidal Neovascularization (Ophthalmology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Choroidal Neovascularization (Ophthalmology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Choroidal Neovascularization (Ophthalmology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Choroidal Neovascularization - Overview
    • Choroidal Neovascularization - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Choroidal Neovascularization - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Choroidal Neovascularization - Companies Involved in Therapeutics Development
    • F. Hoffmann-La Roche Ltd
    • Formycon AG
    • Genentech Inc
    • Graybug Vision Inc
    • Lupin Ltd
    • Mabion SA
    • Navigen Inc
    • NovelMed Therapeutics Inc
    • Noxxon Pharma AG
    • Promedior Inc
  • Choroidal Neovascularization - Drug Profiles
    • ACX-107 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • aflibercept biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • aflibercept biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Antisense Oligonucleotides for Ophthalmology and Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Ayuv-4 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Doxorubicin Pegylated - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Gene Therapy to Activate Calreticulin for Choroidal Neovascularization - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MAb-30D8 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NAV-2729 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NM-9405 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NOXD-20 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PRM-167 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ranibizumab biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ranibizumab biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RG-7716 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule for Inflammation and Choroidal Neovascularization - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Synthetic Peptides for Age Related Macular Degeneration and Choroidal Neovascularization - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Synthetic Peptides to Target VEGF for Choroidal Neovascularization - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Choroidal Neovascularization - Dormant Projects
  • Choroidal Neovascularization - Discontinued Products
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Choroidal Neovascularization, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Choroidal Neovascularization - Pipeline by F. Hoffmann-La Roche Ltd, H1 2017
  • Choroidal Neovascularization - Pipeline by Formycon AG, H1 2017
  • Choroidal Neovascularization - Pipeline by Genentech Inc, H1 2017
  • Choroidal Neovascularization - Pipeline by Graybug Vision Inc, H1 2017
  • Choroidal Neovascularization - Pipeline by Lupin Ltd, H1 2017
  • Choroidal Neovascularization - Pipeline by Mabion SA, H1 2017
  • Choroidal Neovascularization - Pipeline by Navigen Inc, H1 2017
  • Choroidal Neovascularization - Pipeline by NovelMed Therapeutics Inc, H1 2017
  • Choroidal Neovascularization - Pipeline by Noxxon Pharma AG, H1 2017
  • Choroidal Neovascularization - Pipeline by Promedior Inc, H1 2017
  • Choroidal Neovascularization - Dormant Projects, H1 2017
  • Choroidal Neovascularization - Discontinued Products, H1 2017

List of Figures

  • Number of Products under Development for Choroidal Neovascularization, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products by Top 10 Targets, H1 2017
  • Number of Products by Stage and Top 10 Targets, H1 2017
  • Number of Products by Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Molecule Types, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top